The BSH Guidelines Official Podcast

During this podcast, Dr Richard Buka and Prof Deepa Arachchillage discuss the BSH Position Paper ‘Use of andexanet alfa: A British Society for Haematology position statement', published in April 2026.

Dr Will Lester and Dr Ian Jennings discuss the Reporting haemostasis assays in IU/dL—A recommendation for harmonisation (BSH H&T Task Force / UK NEQAS / UK HCDO) paper, published in July 2025.

During this podcast, Matthew Hazell and Lynne Porter discuss the guideline for the estimation of fetomaternal haemorrhage , published in 2026.

During this podcast, Anna Godfrey discusses the Investigation and management of thrombocytosis without JAK2, CALR or MPL mutations Guideline, published in 2025.

During this podcast, Piers Patten and Renata Walewska discuss the Guideline for the treatment of chronic lymphocytic leukaemia, published in 2025.

During this podcast, Dr Austin Kulasekararaj and Dr Lugain Abdalla discuss the Guidelines for the diagnosis and management of adult aplastic anaemia, published in 2024.

In this episode, Dr Charles Percy discusses the joint British Society for Haematology and United Kingdom Haemophilia Centre Doctors' Organisation Guideline on ' Laboratory investigation and clinical management of acquired coagulation factor inhibitors ', published in 2025.

Dr Tracey Chan and Dr Dima El-Sharkawi discuss the Updated guidelines for the diagnosis and management of tumour lysis syndrome in adults and children, published in 2025.

Dr Matthew Wilson, Dr Sridhar Chaganti and Dr Wendy Osborne discuss the Clinical management of bispecific antibody therapy for lymphoma Good Practice Paper, published in 2025.

Dr Eyre is a consultant haematologist specialising in lymphoid malignancies in Oxford. He has completed an MD Doctorate Thesis in 2017. He is an investigator on several national lymphoid trials and has published over 170 peer-review articles on lymphoma and CLL. He is the chair of the low-grade lymphoma clinical trial research group and a core member several lymphoma study groups. He is a member of the BSH guideline writing groups for various lymphoma subtypes and the lead author for the new ESMO Lymphoma guidelines. ​He is also an Associate Editor at the British Journal of Haematology.

Podcast recording by James Griffin on the Guideline: Apheresis procedures for the treatment of patients and for the collection of cellular therapy products.

Dr Deepa J. Arachchillage and Dr Jenny Tam present a review of the Guidelines on the investigation and management of antiphospholipid syndrome. Published: 04 August 2025

Dr Matthew Wilson and Dr Kate Cwynarski discuss the Central nervous system prophylaxis in large B-cell lymphoma Good Practice Paper, published in 2024.

Professor Christopher Fox, Dr Sridhar Chaganti and Dr Bernard Maybury discuss the Management of relapsed or refractory large B-cell lymphoma Guideline, published in 2025.

This podcast is the first of a series of three recordings of the Lymphoma Special Interest Group (SIG) Education Session at the 2025 BSH Annual Scientific Meeting. The Lymphoma SIG is delighted to share talks from three great speakers with the wider audience. In this recording, Dr David Lewis discusses first-line treatment for mantle cell lymphoma in 2025, focusing on three main themes: 1) the emerging use of Bruton’s tyrosine kinase inhibitors (BTKis) in first-line treatment, 2) the role of autologous stem cell transplant, and 3) the clinical utility of minimal residual disease (MRD). Dr David Lewis is a Consultant Haematologist at the University Hospitals Plymouth and an Honorary Associate Professor at the University of Plymouth. He is the Chief Investigator of the ENRICH trial – a randomised, open-label study of Rituximab/Ibrutinib versus. Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma.

Dr Cathy Burton chaired the “Top Abstracts in Lymphoma” session at BSH 2025. In this episode, she shares with us the highlights from this session. Dr Burton is a Consultant Haematologist at St James’s University Hospital, Leeds, specializing in Lymphoma and Diagnostics. She is heavily engaged in translational research in lymphoma and is Chair of the Hodgkin lymphoma study group, Deputy Chair of the Lymphoma Science study group and a member of the UK Lymphoma Research Group. She has recently been involved in writing the diffuse large B cell lymphoma guidelines and is the chair of the BSH Lymphoma Special Interest Group.

Dr Dima El-Sharkawi is a Consultant Haematologist at the Royal Marsden Hospital in Sutton. Her special interests are in CLL, rare leukaemias and lymphomas as well as early phase trials and drug development. She has been an investigator on a number of clinical research studies in these disease groups. She is clinical lead of the Specialist Integrated Haematological Malignancy Diagnostic Services at The Royal Marsden. She is a member of the UK lymphoma research group and CLL trials groups and has co-authored national guidelines for the diagnosis and management of T cell lymphoma and Waldenstrom macroglobulinaemia.

Dr Tracey Chan and Dr Jennifer Pinney discuss the Diagnosis and management of monoclonal gammopathy of renal significance Good Practice Paper, published in January 2025.

In this episode, Dr Sridhar Chaganti shares with us the highlights in large B-cell lymphoma from BSH 2025, including real-world experience in the use of bispecific antibodies and the recent NICE approval of Lisocel as second line treatment. Dr Chaganti is a Consultant Haemato-oncologist at the University Hospital in Birmingham, with an interest in lymphomas, ALL, stem cell transplantation and immune effector cell therapies including CART cell therapy. He is the chair of the high-grade lymphoma study group and co-chairs the national CAR-T panel.